Chroma Therapeutics Ltd.
Records under this name other than patents Chroma Therapeutics Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Chroma Therapeutics Ltd.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,932,246 | Histone Deacetylase Inhibitors Formerly held In force · High confidence | In force | High confidence | |
| US 8,962,825 | Hydroxamates as Inhibitors of Histone Deacetylase Formerly held In force · High confidence | In force | High confidence | |
| US 7,973,181 | Hydroxamic Acid Derivatives as Inhibitors of Hdac Enzymatic Activity Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 9,128,086 | Detection of histone modification in cell-free nucleosomes Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,778,953 | Inhibitors of P38 Map Kinase Formerly held Lapsed on the fee record Ended Jul 15, 2026 · High confidence | Lapsed on the fee record | Ended Jul 15, 2026 | High confidence |
| US 9,896,417 | Tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl]-L-alaninate or a salt,hydrate or solvate thereof Formerly held Lapsed on the fee record Ended Feb 20, 2026 · From the USPTO record | Lapsed on the fee record | Ended Feb 20, 2026 | From the USPTO record |
| US 10,408,831 | Detection of histone modification in cell-free nucleosomes Formerly held Term ended Ended no later than Aug 18, 2024 · From the USPTO record | Term ended | Ended no later than Aug 18, 2024 | From the USPTO record |
| US 9,388,136 | Tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl]-L-alaninate or a salt, hydrate or solvate thereof Formerly held Lapsed on the fee record Ended Jul 12, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jul 12, 2024 | From the USPTO record |
| US 8,044,211 | P38 MAP kinase inhibitors Formerly held Lapsed on the fee record Ended Oct 25, 2023 · From the USPTO record | Lapsed on the fee record | Ended Oct 25, 2023 | From the USPTO record |
| US 9,133,104 | Enzyme inhibitors Lapsed on the fee record Ended Sep 15, 2023 · From the USPTO record | Lapsed on the fee record | Ended Sep 15, 2023 | From the USPTO record |